Alexander Schuth Sells 17,218 Shares of Denali Therapeutics (NASDAQ:DNLI) Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Alexander Schuth sold 17,218 shares of Denali Therapeutics stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $284,097.00. Following the completion of the sale, the insider directly owned 282,828 shares of the company’s stock, valued at $4,666,662. The trade was a 5.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Denali Therapeutics Stock Up 0.1%

DNLI stock opened at $17.08 on Friday. The company has a market cap of $2.50 billion, a price-to-earnings ratio of -5.87 and a beta of 1.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.79 and a current ratio of 9.79. The business’s 50-day moving average is $17.35 and its two-hundred day moving average is $15.66. Denali Therapeutics Inc. has a fifty-two week low of $10.57 and a fifty-two week high of $24.34.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.02. During the same period in the prior year, the company earned ($0.63) EPS. The company’s revenue was up .0% compared to the same quarter last year. As a group, analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Institutional Investors Weigh In On Denali Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DNLI. Headlands Technologies LLC purchased a new position in shares of Denali Therapeutics in the second quarter valued at about $26,000. Johnson Financial Group Inc. purchased a new stake in shares of Denali Therapeutics during the third quarter worth about $29,000. State of Wyoming bought a new stake in Denali Therapeutics during the 2nd quarter valued at approximately $29,000. Quarry LP purchased a new position in Denali Therapeutics in the 3rd quarter worth approximately $64,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Denali Therapeutics by 15.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock worth $79,000 after purchasing an additional 753 shares in the last quarter. 92.92% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, October 8th. Stifel Nicolaus set a $37.00 target price on Denali Therapeutics in a report on Monday, November 17th. JPMorgan Chase & Co. lifted their target price on Denali Therapeutics from $24.00 to $26.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Wedbush reduced their price target on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Thursday, December 11th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Denali Therapeutics in a research note on Friday, December 5th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $32.77.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.